跳至主要内容
临床试验/IRCT20130418013058N17
IRCT20130418013058N17尚未招募2 期

Investigating the effect of crocin on the severity of fatigue, pain and quality of life in patients with multiple sclerosis

Mashhad University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • Definitive diagnosis of MS with neurologist visit, based on the McDonald diagnostic criteria, at least 6 months have passed since the diagnosis.
  • Patients with relapsing-remitting MS or RRMS receiving first- and second-line MS disease therapy.
  • No relapse attacks one month before of the study.
  • Expression of willingness to participate in the study.
  • 0 to 5 points based on expanded disability status scale.
  • ?a fatigue intensity score equal to or higher than 4 according to the Fatigue severity scale
  • Having a feeling of chronic pain in at least one of the body organs and a score higher than 4 based on Numerical rating scale.
  • MS patients who take first and second line drugs (dimethyl fumarate, Resigen, Betaferon, Triflunomide, Fingolimido Cinomer).

排除标准

  • Suffering from other diseases such as (chronic diseases, heart failure, glands, breathing, liver, kidney, skeletal-muscular) and mental diseases and severe depression.
  • Addiction to alcohol, drugs and psychedelics
  • History of allergy to saffron
  • Pregnancy and breastfeeding
  • The presence of severe infection and inflammation, varicose veins, active thrombosis, damage to organs such as fractures.
  • Motor disability score higher than 6
  • Getting any other serious diseases such as heart, liver and kidney diseases during treatment
  • Do heavy exercise daily
  • Any use of anti-inflammatory and antioxidant drugs as a supplement or Amantadine as an anti-fatigue drug
  • Unwillingness to participate in the study or continue the treatment process

研究者

相似试验